Related Experiment Video
Updated: Sep 25, 2025
07:49
Stepwise Cell Seeding on Tessellated Scaffolds to Study Sprouting Blood Vessels
Published on: January 14, 2021
3.6K
Scaffold Engineering with Flavone-Modified Biomimetic Architecture for Vascular Tissue Engineering Applications
Chao Xie1,2, Ting Guo2, Wei Wang1
1Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Tissue Engineering and Regenerative Medicine
|April 28, 2022
Summary
This study developed a novel tissue-engineered vascular scaffold using portulaca flavonoid (PTF) and poly(ε-caprolactone) (PCL). The PCL/PTF scaffold effectively inhibits vascular intimal hyperplasia without cytotoxicity, offering a promising solution for small-diameter vascular grafts.
Area of Science:
- Biomaterials Science
- Tissue Engineering
- Regenerative Medicine
Background:
- Vascular intimal hyperplasia (IH) is a major limitation for small-diameter vascular grafts.
- Existing tissue engineering strategies primarily address vascularization and antithrombotics, with limited focus on IH treatment.
- This research introduces a novel approach targeting IH through a specifically designed tissue-engineered vascular scaffold.
Purpose of the Study:
- To design and fabricate a tissue-engineered vascular scaffold incorporating portulaca flavonoid (PTF) and poly(ε-caprolactone) (PCL).
- To evaluate the scaffold's material properties, cellular biocompatibility, and efficacy in inhibiting vascular smooth muscle cell proliferation.
- To explore the potential of this scaffold as a substitute for small-diameter vascular grafts, addressing the challenge of IH.
Main Methods:
- Electrospinning was employed to integrate PTF with biodegradable PCL, creating a bionic vascular scaffold.
- Material characterization and cellular biocompatibility assessments were performed using human vascular smooth muscle cells (HVSMCs).
- HVSMCs were cultured on the scaffolds for up to 14 days to evaluate cell behavior and proliferation.
Main Results:
- The PCL/PTF scaffold exhibited enhanced hydrophilicity and degradability compared to the PCL-only scaffold.
- Scaffold morphology, including fiber diameter, structure, and orientation, was influenced by PTF incorporation and fabrication parameters.
- The PCL/PTF (9.1%) scaffold demonstrated significant inhibition of HVSMC proliferation without inducing cytotoxicity, while promoting contact guidance for cell morphology.
Conclusions:
- The developed PCL/PTF scaffold offers a promising strategy to mitigate restenosis caused by intimal hyperplasia.
- This engineered vascular scaffold possesses complex functions and a well-defined preparation method.
- The scaffold is expected to serve as a viable substitute for small-diameter vascular grafts, addressing a critical clinical need.
